Will immunotherapy add value to chemotherapy for HER-2 positive gastric cancer?

(European Organisation for Research and Treatment of Cancer) EORTC trial 1203 -- Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer, is open for recruitment for patients with early, HER-2 positive gastric cancer. This phase II, randomized EORTC study was developed to investigate the added value of a perioperative treatment regimen which includes HER-2 targeting drugs for patients with gastric and gastro-esophageal junction cancers.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news